Experimental drug slows tumor growth
Key points
- Amgen Inc. and Abgenix Inc. said on Thursday a late-stage study found its experimental drug panitumumab helped slow tumor progression in patients with advanced Colon cancer who had failed multiple other therapies.
- In the 463-patient trial, patients who received panitumumab every two weeks showed a 46 percent decrease in tumor progression rate versus those who received best supportive care alone, the companies said.
- The result was better than the pre-set goal of a 33 percent decrease in tumor progression, they said.
- "We are very encouraged by the results of this pivotal study and what panitumumab could mean for patients with advanced Colorectal cancer," said Bill Ringo, president and chief executive officer of Abgenix.
Amgen Inc. and Abgenix Inc. said on Thursday a late-stage study found its experimental drug panitumumab helped slow tumor progression in patients with advanced Colon cancer who had failed multiple other therapies.
In the 463-patient trial, patients who received panitumumab every two weeks showed a 46 percent decrease in tumor progression rate versus those who received best supportive care alone, the companies said.
The result was better than the pre-set goal of a 33 percent decrease in tumor progression, they said.
"We are very encouraged by the results of this pivotal study and what panitumumab could mean for patients with advanced Colorectal cancer," said Bill Ringo, president and chief executive officer of Abgenix.
The news sent shares of Amgen and Abgenix sharply higher while dragging down shares of ImClone Systems Inc., maker of a rival drug.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsCelldex breast cancer drug shrinks some tumors: study
Interim results from a mid-stage trial of Celldex Therapeutics Inc's experimental drug showed trends toward reducing tumors in patients with advanced breast cancer, with rates improving for those patients with high…
24 May 2012
NewsCurry Spice Component May Help Slow Prostate Tumor Growth
Curcumin, an active component of the Indian curry spice turmeric, may help slow down tumor growth in castration-resistant prostate cancer patients on androgen deprivation therapy (ADT), a study from researchers at…
13 February 2012
NewsFibroblasts Contribute To Melanoma Tumor Growth
Fibroblasts, cells that play a role in the structural framework of tissues, play an apparent role in melanoma tumor growth. Fibroblasts also contribute to melanoma drug resistance and may also facilitate the “flare”…
8 January 2012
